Want to see IOVA full AI Analyst Report?
IOVA Stock Chart & Stats
$3.86
-$0.33(-4.53%)
At close: 4:00 PM EST
$3.86
-$0.33(-4.53%)
Day’s Range― - ―
52-Week Range$1.76 - $5.63
Previous CloseN/A
Volume2.95M
Average Volume (3M)15.04M
Market Cap
$2.23B
Enterprise Value$1.20K
Total Cash (Recent Filing)$313.44M
Total Debt (Recent Filing)$47.78M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding446,502,400
10 Day Avg. Volume18,042,671
30 Day Avg. Volume15,044,043
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.80Price Target Upside153.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$362.04M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue AccelerationSustained, high-single quarter revenue growth reflects that AMTAGVI has transitioned from trial-stage to a meaningful commercial product. Over months this supports predictable per-patient revenue, broadens payer negotiations, and validates the sales model needed to scale treatment volumes and long-term revenue cadence.
In-house Manufacturing ControlOwning and restoring in-house modular manufacturing reduces reliance on third parties, improves throughput predictability, and supports margin preservation as volumes grow. Over the medium term this strengthens supply security for patient-specific therapies and lowers scaling risk versus outsourced models.
Balance Sheet Resilience And Capital FlexibilityLow leverage and a substantial equity base provide financial optionality to fund commercialization and clinical programs without heavy near-term debt service. Combined with recent authorization actions and shelf filings, this structural flexibility supports multi-year operations and strategic investments while execution continues.
Bears Say
Large Operating Cash BurnPersistent, sizable negative operating and free cash flow creates an ongoing need for financing and constrains reinvestment. Unless revenues scale faster than costs, cash burn will force continued capital raises or spending cuts, which can dilute shareholders or slow commercialization and R&D progress over the next 2–6 months.
Deep Net Losses And Negative MarginsSignificant cumulative losses and wide negative margins indicate the company is far from break-even despite revenue gains. Structural profitability depends on volume scale, margin expansion and tighter operating discipline; failure to materially improve these metrics risks continued value erosion over months.
Financing And Dilution Risk From ATM/shelfReliance on ATM programs, expanded share authorization, and a recently filed mixed securities shelf signal structural funding reliance. Ongoing equity issuance risk can dilute existing holders and affects long-term capital structure, potentially limiting shareholder value unless operational cash flow materially improves.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was $1.76 and its highest was $5.63 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $2.23B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.154 by -$0.036.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.13.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 446,502,400 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.154. Following the earnings report the stock price went down -13.203%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in IOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.80 (153.89% Upside)
$9.80 (153.89% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 571.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
IOVA Stock 12 Month Forecast
Average Price Target
$9.80
▲(153.89% Upside)
Technical Analysis
Ownership Overview
0.32% Insiders
12.27% Mutual Funds
0.53% Other Institutional Investors
69.97% Public Companies and Individual Investors